hotspot -WSS

hotspot

author：focus 2025-09-27 10:04:26 - browse：7941

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： 6 phony surgeries that take placebo to the extreme

WSS

Obesity drugs seen as possible treatment for liver disease MASH

Alabama frozen embryo ruling has major implications for IVF clinics

A new nitrogen execution bill also undermines medical licensing

Sutter Health’s antitrust win overturned by appeals court

Anthony Fauci pushes back on GOP claims during Covid hearing

New documents shed light on MD Anderson Cancer Institute feud

entertainment

hotspot

Lobbying power of AI, software-enabled devices

hotspot

Alkermes shareholders re

A new nitrogen execution bill also undermines medical licensing

Hepatitis C has a cure — but many Americans still lack access to it

FDA approves Moderna’s RSV vaccine, its second licensed product

The high cost of giving birth even with insurance

An outdated Medicare rule harms dementia patients with anxiety

The high cost of giving birth even with insurance

FDA approves Moderna’s RSV vaccine, its second licensed product

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Sutter Health’s antitrust win overturned by appeals court

focus

Finland to offer bird flu vaccine to select groups of people, a possible global first

NIH study of ME/CFS points to clear biological hallmarks

Anthony Fauci pushes back on GOP claims during Covid hearing

Medicare Advantage's lean provider networks lead CMS complaints

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Illumina board agrees to spin off Grail, as divestment plans proceed

Wikipedia

focus

knowledge

entertainment